

## **A Declaration of Joint Working Between**

AstraZeneca UK Limited,  
Huma Therapeutics Limited  
and SWB Modality PCN

Modality SWB PCN % Modality Medical Services Limited, Huma Therapeutics Limited and AstraZeneca UK Limited are engaged in a Joint Working Agreement called “***UK Asthma Review***”.

The overall aim of this Joint Working Agreement is to collaborate to explore the value of digital first review and support for asthma patients with their annual asthma review. Through this project, the Parties aim to demonstrate the value of a digital pathway to engage, triage and review asthma patients in the primary care setting and providing ongoing support through an asthma disease management platform to engage and monitor patients outside of the clinical setting with the Modality SWB PCN.

The objectives of this project are:

- Optimising asthma management for asthmatic patients according to guideline-based medical therapy.
- Support GPs and primary care teams to help annual review targets.
- Improving patient experience, convenience and accessibility driving improved patient engagement in their asthma management.

The potential benefits of this approach are:

- Improved identification and engagement of asthma patients within the asthma register.
- Improved efficiencies in workflow by easing the resource strain on clinical team to engage and book-in patients for review.
- Delivering more appropriate appointments to the patient through patient triage compared to current state.
- Improve control of asthma for patients through provisioning of asthma reviews and appropriate asthma management plans in-line according to guideline-based medical therapy.
- Support practices meet QOF indicators targets to deliver quality care to asthma patients.
- Provide ongoing support through an asthma disease management platform to empower patients to take control of their disease through education materials and support virtual monitoring to create clinical efficiencies by reducing unplanned visits and seeing the right patient at the right time.

The data collected in this program will be analyzed to determine benefits to asthma patients and primary care teams, assess the feasibility of scaling the programme more broadly and utilize the outcomes of the pilot report to determine impact generated and serve as learning for future potential implementations. The project will run from September 2023 to March 2024. All parties have contributed resources to this initiative.